Comparison between Prostarm Info Systems IPO and Veeda Clinical Research IPO.
Prostarm Info Systems IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Veeda Clinical Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Prostarm Info Systems IPO is up to ₹168.00 Cr whereas the issue size of the Veeda Clinical Research IPO is up to ₹0.00 Cr. The final issue price of Prostarm Info Systems IPO is ₹105.00 per share and of Veeda Clinical Research IPO is .
| Prostarm Info Systems IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ₹95.00 per share | |
| Issue Price (Upper) | ₹105.00 per share | |
| Issue Price (Final) | ₹105.00 per share | |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ||
| Market Lot Size | 142 shares | |
| Fresh Issue Size | 1,60,00,000 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹168.00 Cr | up to ₹185.00 Cr |
| OFS Issue Size | 0 shares | 1,30,08,128 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 1,60,00,000 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹168.00 Cr | up to ₹0.00 Cr |
Prostarm Info Systems IPO opens on May 27, 2025, while Veeda Clinical Research IPO opens on . The closing date of Prostarm Info Systems IPO and Veeda Clinical Research IPO is May 29, 2025, and , respectively.
| Prostarm Info Systems IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Bid Date | May 26, 2025 | |
| Issue Open | May 27, 2025 | |
| Issue Close | May 29, 2025 | |
| Basis Of Allotment (Tentative) | May 30, 2025 | |
| Initiation of Refunds (Tentative) | Jun 02, 2025 | |
| Credit of Share (Tentative) | Jun 02, 2025 | |
| Listing date (Tentative) | Jun 03, 2025 | |
| Anchor Lockin End date 1 | Jun 28, 2025 | |
| Anchor Lockin End date 2 | Aug 28, 2025 |
Prostarm Info Systems IPO P/E ratio is 19.75, as compared to Veeda Clinical Research IPO P/E ratio of .
| Prostarm Info Systems IPO | Veeda Clinical Research IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 33.83 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 19.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹618.18 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 31.41% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 32.41% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.51 | 0.32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹5.32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 32.09% | -0.02% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Prostarm Info Systems IPO Retail Individual Investors (RII) are offered 56,00,000 shares while in Veeda Clinical Research IPO retail investors are offered 56,00,000 shares. Qualified Institutional Buyers (QIB) are offered 32,00,000 shares in Prostarm Info Systems IPO and in Veeda Clinical Research IPO.
| Prostarm Info Systems IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Investor Reservation | 48,00,000 shares | |
| Market Maker Reservation | ||
| QIB | 32,00,000 shares | |
| NII | 24,00,000 shares | |
| RII | 56,00,000 shares | |
| Employee | ||
| Others | ||
| Total | 1,60,00,000 shares |
Prostarm Info Systems IPO subscribed 96.68x in total, whereas Veeda Clinical Research IPO subscribed .
| Prostarm Info Systems IPO | Veeda Clinical Research IPO | |
|---|---|---|
| QIB (times) | 102.67x | |
| NII (times) | 222.13x | |
| Big NII (times) | 249.80x | |
| Small NII (times) | 166.78x | |
| RII (times) | 39.48x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 96.68x |
